Insmed Incorporated Stock

Equities

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-07-18 EDT 5-day change 1st Jan Change
75.06 USD -0.64% Intraday chart for Insmed Incorporated -2.56% +142.21%
Sales 2024 * 353M 484M Sales 2025 * 529M 725M Capitalization 12.1B 16.59B
Net income 2024 * -738M -1.01B Net income 2025 * -653M -895M EV / Sales 2024 * 35.6 x
Net Debt 2024 * 456M 625M Net Debt 2025 * 580M 796M EV / Sales 2025 * 24 x
P/E ratio 2024 *
-16.2 x
P/E ratio 2025 *
-19 x
Employees 912
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.99%
More Fundamentals * Estimated data
Dynamic Chart
1 day-0.64%
1 week-2.56%
Current month+12.03%
1 month+14.46%
3 months+202.66%
6 months+163.92%
Current year+142.21%
More quotes
1 week
73.70
Extreme 73.7
78.87
1 month
61.52
Extreme 61.52
78.87
Current year
21.92
Extreme 21.92
78.87
1 year
20.16
Extreme 20.164
78.87
3 years
16.04
Extreme 16.04
78.87
5 years
12.09
Extreme 12.09
78.87
10 years
9.02
Extreme 9.02
78.87
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 12-09-09
Director of Finance/CFO 43 20-01-30
Chief Tech/Sci/R&D Officer 60 19-12-18
Members of the board TitleAgeSince
Director/Board Member 60 20-03-31
Director/Board Member 65 12-08-01
Director/Board Member 73 01-04-30
More insiders
Date Price Change Volume
24-07-18 75.06 -0.64% 2,390,655
24-07-17 75.54 -3.13% 2,271,967
24-07-16 77.98 +0.66% 2,077,625
24-07-15 77.47 +0.99% 2,183,535
24-07-12 76.71 -0.42% 4,877,109

Delayed Quote Nasdaq, July 18, 2024 at 04:00 pm

More quotes
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
75.06 USD
Average target price
82.62 USD
Spread / Average Target
+10.08%
Consensus